Compare GDRX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | TNDM |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.1M | 1.1B |
| IPO Year | 2020 | 2013 |
| Metric | GDRX | TNDM |
|---|---|---|
| Price | $2.81 | $17.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 19 |
| Target Price | $3.66 | ★ $28.00 |
| AVG Volume (30 Days) | 1.8M | ★ 3.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $796,853,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | $5.38 | $11.85 |
| P/E Ratio | $28.94 | ★ N/A |
| Revenue Growth | 0.57 | ★ 7.93 |
| 52 Week Low | $1.77 | $10.00 |
| 52 Week High | $5.61 | $29.65 |
| Indicator | GDRX | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 52.95 |
| Support Level | $2.64 | $12.75 |
| Resistance Level | $2.95 | $21.68 |
| Average True Range (ATR) | 0.15 | 1.20 |
| MACD | 0.02 | 0.62 |
| Stochastic Oscillator | 53.57 | 69.15 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.